Beraprost
From Wikipedia, the free encyclopedia
Beraprost
|
|
Systematic (IUPAC) name | |
2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4- methyl-1-octen-6-ynyl)-1H-cyclopenta(b)benzofuran- 5-butanoic acid |
|
Identifiers | |
CAS number | 88475-69-8 (sodium salt) |
ATC code | B01 |
PubChem | |
Chemical data | |
Formula | C24H30O5 |
Mol. mass | 398.492 g/mol |
Pharmacokinetic data | |
Bioavailability | 50–70% |
Metabolism | Unknown |
Half life | 35–40 minutes |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status |
? |
Routes | Oral |
Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.
[edit] Clinical pharmacology
As an analogue of prostacyclin PGI2, beraprost effects vasodilation, which in turn lowers the blood pressure. Beraprost also inhibits platelet aggregation, though the role this phenomenon may play in relation to pulmonary hypertension has yet to be determined.
[edit] Dosage and administration
Beraprost is administered orally as a pill.
Alprostadil - Dinoprostone - Prostacyclin
Prostaglandin analogues: Beraprost - Bimatoprost - Carboprost - Enprostil - Iloprost - Latanoprost - Misoprostol - Travoprost - Treprostinil